The hepatitis C drug Sovaldi is a $1,000-per-pill treatment that insurers are reluctant to pay for. Groundbreaking treatments for pervasive diseases such as hepatitis C could cure millions of Americans, but staggering prices are eclipsing this potential.
The hepatitis C drug Sovaldi is a $1,000-per-pill treatment that insurers are reluctant to pay for. Groundbreaking treatments for pervasive diseases such as hepatitis C could cure millions of Americans, but staggering prices are eclipsing this potential. Uncredited Gilead Sciences
The hepatitis C drug Sovaldi is a $1,000-per-pill treatment that insurers are reluctant to pay for. Groundbreaking treatments for pervasive diseases such as hepatitis C could cure millions of Americans, but staggering prices are eclipsing this potential. Uncredited Gilead Sciences

Soapbox

Another View: State needs to know more about drug prices

April 20, 2015 5:00 PM

Comments

Videos